ClinicalTrials.gg
Active, not recruitingNCT05995964Updated Oct 23, 2026

A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis

A Phase 2 interventional study of PF-07275315 and PF-07264660 in Atopic Dermatitis, sponsored by Pfizer. Active, not recruiting at 96 sites in 7 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-23.

Sponsored by Pfizer · Phase 2, Interventional, and Treatment

Updated Oct 23, 2026Now Active, not recruitingPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
507
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 58 studies in Dermatitis, Atopic by Pfizer — 11 open to participants now, 13 under way, 4 of them phase 3. Dermatitis, Atopic · Pfizer.

Enrollment
9th of 47
507 · median 121
Started
2023
with 4 others
Phase 2
13 of 58
1 open now
Primary completion
2026-11
later than 0 of 12 live
Registered
45th of 58
by date

Among the 58 studies in Dermatitis, Atopic by Pfizer, this one is the 9th largest by enrollment of the 47 interventional ones that give a count, is one of 5 that started in 2023, is one of 13 in phase 2, reaches primary completion later than 0 of the 12 other live ones, and was the 45th registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

11 of the 58 studies in Dermatitis, Atopic by Pfizer are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 58 studies in Dermatitis, Atopic by Pfizer, or all of them as a file.
02

Study summary

The purpose of this study is to learn about the safety and effects of 2 study medicines (PF-07275315 and PF-07264660) for the treatment of atopic dermatitis (AD). AD is a long- lasting itchy red rash, caused by a skin reaction.

This study is seeking participants who:

  • are 18 years of age or more.
  • Were confirmed to have AD at least 6 months ago.
  • Are not having an effective treatment result from medicines that are applied on skin for AD.
  • Are considered by their doctors to have moderate to severe AD.

In Stage 1 of the study, participants will receive either PF-07275315 or PF-07264660 or placebo. Stage 1 is complete. In Stage 2 of the study participants will receive either PF-07275315 or placebo. In Stage 3 of the study participants who have received anti-inflammatory proteins, will receive either PF-07275315 or placebo. In Stage 4 of the study participants will receive either PF-07264660 or placebo. A placebo does not have any medicine in it but looks just like the medicines being studied.

PF-07275315 or PF-07264660 or placebo will be given as multiple shots in the clinic over the course of each Stage.

The experiences of people receiving PF-07275315 or PF-07264660 will be compared to people who do not. This will help determine if PF-07275315 and PF-07264660 are safe and effective.

Participants in Stages 1, 2 and 4 will be involved in this study for up to 40 weeks (10 months). Participants in Stage 3 will be involved in this study for up to 52 weeks (13 months).

03

Conditions studied

  • Atopic Dermatitis

Keywords

  • Eczema
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Must meet the following AD criteria:

  1. Participants aged 18 years or older
  2. Clinical diagnosis of chronic atopic dermatitis:

    1. for at least 6 months prior to Day 1 with diagnosis confirmed by photograph;
    2. Either an inadequate response to treatment with standard of care treatments (excluding systemic treatments) for at least 4 consecutive weeks within 6 to 12 months of the first dose of the study intervention; OR documented reason why topical treatments are considered medically inappropriate;
    3. Moderate to severe AD defined as having an affected BSA ≥10%, vIGA ≥3, and EASI ≥16 at both the screening and baseline visits).
    4. Bio-experienced cohort-partial or non-responder to anti-inflammatory proteins (also known as biologics), intolerance or AEs to anti-inflammatory proteins or loss of access to anti-inflammatory proteins with ≥12 weeks of treatment within 5 years.

    Other Inclusion Criteria:

  3. of 17.5 to 40 kg/m2; and a total body weight >45 kg (100 lbs).
  4. Willing and able to comply with all scheduled visits, treatment plan, laboratory tests and other study procedures.

Exclusion criteria

Exclusion Criteria:

- Medical Conditions:

  1. Significant allergic or diseases, other than AD and well controlled mild to moderate including but not limited to: SLE or other complement disorders; Type 1 diabetes; IBD; Multiple Sclerosis.
  2. History of significant allergic reactions, including anaphylaxis and reactions to protein therapeutics, including to PF-07275315 or PF-07264660 or to the of the formulated drug products. Participants with significant reactions to single, identified, avoidable allergens (eg, peanut allergy) may be eligible if avoidance of these allergens during the study is feasible.
  3. Any of the following acute or chronic infections or infection history:

    1. Active infection (including helminth or parasitic) requiring treatment within 2 weeks prior to screening;
    2. Infection requiring hospitalization or systemic (parenteral) antimicrobial therapy within 60 days prior to Day 1;
    3. Active chronic or acute skin infection requiring treatment with systemic [(not IV)] antibiotics, antivirals, antiparasitics, antiprotozoals, or antifungals within 2 weeks prior to Day 1, or superficial skin infections (requiring no more than topical anti-infective treatments) within 1 week prior to Day 1.
    4. Any infection judged to be an opportunistic infection or by the investigator, within 6 months prior to Day 1;
  4. History of or current evidence of inflammatory skin conditions (eg, psoriasis, seborrheic dermatitis, lupus) at the time of Day 1 that could interfere with evaluation of AD or response to treatment.
  5. Any medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.

    - Prior/Concomitant Therapy:

  6. Current use of any prohibited concomitant medication(s).
  7. Phototherapy narrowband UVB (NB UVB) or broadband phototherapy or regular use (more than 2 visits per week) of a tanning booth/parlor within 4 weeks prior to Day 1.

    - Prior/Concurrent Clinical Study Experience:

  8. Previous administration with an product (drug or vaccine) within 30 days (or as determined by the local requirement) or 5 half lives preceding the first dose of study intervention used in this study (whichever is longer).
  9. infection, or infection with or viruses according to protocol-specific testing algorithm.
  10. Evidence of active or latent TB, or inadequately treated infection with Mycobacterium TB. A participant who is currently being treated for active or latent TB infection must be excluded from this study.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
507 participants (actual)

Study arms

  • Experimental
    Stage 1_PF-07275315

    Stage 1 PF-07275315 Injections over 12 weeks

    Drug: PF-07275315

  • Experimental
    Stage 1_PF-07264660

    Stage 1 PF-07264660 Injections over 12 weeks

    Drug: PF-07264660

  • Experimental
    Stage 1_Placebo

    Stage 1 Placebo Injections over 12 weeks

    Other: Placebo

  • Experimental
    Stage 2_PF-07275315 _Dose A

    Stage 2 PF-07275315 Injections over 12 weeks.

    Drug: PF-07275315

  • Experimental
    Stage 2_PF-07275315 _Dose B

    Stage 2 PF-07275315 Injections over 12 weeks.

    Drug: PF-07275315

  • Experimental
    Stage 2_PF-07275315 _Dose C

    Stage 2 PF-07275315 Injections over 12 weeks.

    Drug: PF-07275315

  • Experimental
    Stage 2_PF-07275315 _Dose D

    Stage 2 PF-07275315 or PF-07264660 Injections over 12 weeks.

    Drug: PF-07275315 · Drug: PF-07264660

  • Experimental
    Stage 2_Placebo

    Stage 2 Placebo Injections over 12 weeks.

    Other: Placebo

  • Experimental
    Stage 3_Placebo+PF-07275315_Dose A

    Stage 3 Placebo Injections for 16 weeks followed by PF-07275315 Injections for 16 weeks.

    Drug: PF-07275315 · Other: Placebo

  • Experimental
    Stage 3_PF-07275315_Dose B

    Stage 3 PF-07275315 Injections for 32 weeks.

    Drug: PF-07275315

  • Experimental
    Stage 4_PF-07264660_Dose A

    Stage 4 PF-07264660 Injections for 12 weeks

    Drug: PF-07264660

  • Experimental
    Stage 4_PF-07264660_Dose B

    Stage 4 PF-07264660 Injections for 12 weeks

    Drug: PF-07264660

  • Experimental
    Stage 4_PF-07264660_Dose C

    Stage 4 PF-07264660 Injections for 12 weeks

    Drug: PF-07264660

  • Experimental
    Stage 4_Placebo

    Stage 2 Placebo Injections for 12 weeks

    Other: Placebo

Interventions

06

What researchers measure

Primary outcomes

  1. The number of participants achieving ≥75% improvement in EAS175 from baseline at week16.

    EASI75 (≥75% improvement from baseline) at Week 16

    Time frame: Week 16

Secondary outcomes

  1. The number and % of participants achieving vIGA score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at all scheduled time points

    vIGA score of clear (0) or almost clear (1) (on a 5-point scale) and a reduction from baseline of ≥2 points at all scheduled time points

    Time frame: Screening through study completion, an average of 36 weeks.

  2. The number and % of participants achieving EASI75 (≥75% improvement from baseline) at scheduled time points except Week 16

    EASI75 (≥75% improvement from baseline) at scheduled time points except Week 16

    Time frame: All scheduled timepoints other than Week 16, screening through study completion, an average of 36 weeks.

  3. The number and % of participants achieving a Percent change from baseline in EASI total score at scheduled time points

    Percent change from baseline in EASI total score at scheduled time points

    Time frame: Screening through study completion, an average of 36 weeks.

  4. The number and % of participants with treatment emergent AEs

    Incidence of treatment emergent AEs

    Time frame: Screening - Week 36

  5. The number and % of participants with clinically significant changes in vital signs

    Incidence of clinically significant changes in vital signs

    Time frame: Screening - Week 36

  6. The number and % of participants with clinically significant changes in ECG

    Incidence of clinically significant changes in ECG

    Time frame: Screening - Week 36

  7. The number and % of participants with clinically significant changes in laboratory tests

    Incidence of clinically significant changes in laboratory tests

    Time frame: Screening - Week 36

07

Study locations

96 sites
08

References and documents

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Nov 2026, 38 months after the start.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's planned 38 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 23, 2026: primary completion Oct 2026 → Nov 2026 and completion Mar 2027 → Apr 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 26, 2023
First posted
Aug 16, 2023
StartActual
Aug 22, 2023
Primary completionEst.
Nov 12, 2026was Oct 2026
CompletionEst.
Apr 1, 2027was Mar 2027
Last update
Oct 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 23, 2026
Sites
3 sites added, 5 sites removed
Show 3 added (2 China, 1 Canada)
  • Centre de Recherche Saint-Louis inc. · Québec, Canada
  • The First Affiliated Hospital of Fujian Medical University · Fuzhou, China
  • The First Hospital of Wuhan · Wuhan, China
Show 5 removed
  • Medical Dermatology Specialists · Phoenix, United States
  • National Allergy and Asthma · North Charleston, United States
  • Centre de Recherche Saint-Louis inc. · Québec, Canada
  • Affiliated Hospital of Jiangsu University · Zhenjiang, China
  • Zhejiang Provincial People's Hospital · Hangzhou, China
Oct 23, 2026
Primary completion
Oct 19, 2026→Nov 12, 2026
Oct 23, 2026
Study completion
Mar 8, 2027→Apr 1, 2027
Oct 23, 2026
Enrollment
340 (estimated)→507 (actual)
Oct 23, 2026
Show all 1 update
  1. Oct 23, 2026
    Recruiting→Active, not recruiting
    3 sites added, 5 sites removed
    Show 3 added (2 China, 1 Canada)
    • Centre de Recherche Saint-Louis inc. · Québec, Canada
    • The First Affiliated Hospital of Fujian Medical University · Fuzhou, China
    • The First Hospital of Wuhan · Wuhan, China
    Show 5 removed
    • Medical Dermatology Specialists · Phoenix, United States
    • National Allergy and Asthma · North Charleston, United States
    • Centre de Recherche Saint-Louis inc. · Québec, Canada
    • Affiliated Hospital of Jiangsu University · Zhenjiang, China
    • Zhejiang Provincial People's Hospital · Hangzhou, China
    Primary completion Oct 19, 2026→Nov 12, 2026
    Study completion Mar 8, 2027→Apr 1, 2027
    Enrollment 340 (estimated)→507 (actual)
    + 3 other changes: identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05995964
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Aug 16, 2023
Start date
Aug 22, 2023
Primary completion
Nov 12, 2026 (estimated)
Completion
Apr 1, 2027 (estimated)
Last update
Oct 23, 2026

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Tilrekimig · Ompekimig

Start the discussion